Ahmed K Elhady

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4888654/publications.pdf

Version: 2024-02-01

10 papers	137 citations	1477746 6 h-index	1372195 10 g-index
10 all docs	10 docs citations	10 times ranked	191 citing authors

#	Article	IF	Citations
1	Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/Î±-synuclein aggregation inhibitors with neuroprotective effects. European Journal of Medicinal Chemistry, 2022, 227, 113911.	2.6	11
2	Development of novel conformationally restricted selective Clk1/4 inhibitors through creating an intramolecular hydrogen bond involving an imide linker. European Journal of Medicinal Chemistry, 2022, 238, 114411.	2.6	4
3	5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency. Molecules, 2021, 26, 1001.	1.7	4
4	Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases. ACS Chemical Neuroscience, 2021, 12, 4302-4318.	1.7	4
5	Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. Bioorganic Chemistry, 2020, 98, 103742.	2.0	14
6	Development of novel amideâ€“derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. European Journal of Medicinal Chemistry, 2018, 158, 270-285.	2.6	16
7	Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins. Journal of Medicinal Chemistry, 2017, 60, 5377-5391.	2.9	41
8	Structure-Based Design of Novel Tetrahydro-Beta-Carboline Derivatives with a Hydrophilic Side Chain as Potential Phosphodiesterase Inhibitors. Scientia Pharmaceutica, 2016, 84, 428-446.	0.7	6
9	Pharmacological inhibition of protein kinase C (PKC)Î¶ downregulates the expression of cytokines involved in the pathogenesis of chronic obstructive pulmonary disease (COPD). European Journal of Pharmaceutical Sciences, 2016, 93, 405-409.	1.9	14
10	Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism. European Journal of Medicinal Chemistry, 2016, 112, 171-179.	2.6	23